Georgian Scientists
ქართველი მეცნიერები
Vol. 7 Issue 4, 2025
https://doi.org/10.52340/gs.2025.07.04.44



Advances, Clinical Translation and Emerging Challenges In Gene Therapy: From Viral Vector Engineering And Genome Editing To Precision And Personalized Genetic Medicine

Nodar Sulashvili[1], Igor Seniuk[2], Vira Kravchenko[3], Irina Imerlishvili[4], Luiza Gabunia[5], Nana Gorgaslidze[6], Maka Buleishvili[7], Marika Sulashvili[8], Rajkaran Singh[9], Deva Harsha Uday Gundluru[10], David Aphkhazava[11]

1. MD, PhD, Doctor of Pharmaceutical and Pharmacological Sciences in Medicine, Invited Lecturer (Invited Professor) of Scientific Research-Skills Center at Tbilisi State Medical University; Professor of Medical Pharmacology of Faculty of Medicine at Georgian National University SEU; Professor of Medical and Clinical Pharmacology of International School of Medicine at Alte University; Tbilisi, Georgia; Orcid https://orcid.org/0000-0002-9005-8577; E-mail: n.sulashvili@ug.edu.ge
2. PhD, Doctor of Pharmaceutical Sciences, Dean of faculty of Pharmacy at National University of Pharmacy of Ukraine, Associate Professor of Biological Chemistry Department at National University of Pharmacy of Ukraine, https://orcid.org/0000-0003-3819-733; Kharkiv, Ukraine.
3. MD, PhD, Doctor of Biological Sciences, Academician, Professor, Head of The Biological Chemistry Department at National University of Pharmacy of Ukraine, Kharkiv, Ukraine. https://orcid.org/0000-0001-6335-2490
4. PhD, Doctor of Law, Professor, Rector of BAU International University Batumi; Professor of BAU International University Batumi; Professor at the International Black Sea University, Batumi-Tbilisi, Georgia;
5. MD, PhD, Doctor of Medical Sciences, Professor, Director of the Scientific Research-Skills Center at Tbilisi State Medical University, Professor, Head of the Department of Medical and Clinical Pharmacology at Tbilisi State Medical University, Clinical Pharmacologist of The First University Clinic of TSMU, Tbilisi, Georgia; https://orcid.org/0000-0003-0856-2684
6. MD, PhD, Doctor of Pharmaceutical Sciences, Academician, Professor of Tbilisi State Medical University, Head of The Department of Social and Clinical Pharmacy, Tbilisi, Georgia; https://orcid.org/0000-0002-4563-5224
7. MD, PhD, Doctor of Medical Sciences, Professor, Dean of Faculty of Medicine of BAU International University Batumi, Professor of Faculty of Medicine at European University, Professor of Faculty of Medicine at Georgian National University SEU, Professor of Faculty of Medicine at Sulkhan-Saba Orbeliani University, Invited Professor of Faculty of Healthcare Sciences at East European University, Invited Professor of Faculty of Medicine at Caucasus International University, Invited Lecturer of Tbilisi State Medical University, Tbilisi, Georgia; https://orcid.org/0009-0004-2657-8473
8. MD, Doctor of Family Medicine, Invited Lecturer of Tbilisi State Medical University, Department of Molecular and Medical Genetics; Invited Lecturer of Family Medicine of Faculty of Medicine at Georgian National University SEU; Invited Professor of Biochemistry and Molecular and Medical Genetics at The University of Georgia; Tbilisi, Georgia;

9. MD student of Medical Doctor Degree Program of Faculty of Medicine at Georgian National University SEU; Tbilisi, Georgia; https://orcid.org/0009-0000-4903-0145
10. MD student of Medical Doctor Degree Program of Faculty of Medicine at University of Georgia, Tbilisi, Georgia;
11. PhD, Doctor of Biological Sciences, Invited Professor of Biochemistry of University of Georgia, Tbilisi Georgia; Orcid: https://orcid.org/0000-0001-6216-6477

Abstract

The advent of genome editing technologies, most notably CRISPR-Cas systems, has further expanded the therapeutic scope of gene therapy by enabling precise modification of endogenous DNA. Genome editing allows direct correction of pathogenic mutations, targeted gene disruption, and modulation of gene expression, marking a conceptual shift from gene addition toward permanent genetic repair. The clinical approval of CRISPR-based therapies and the rapid translation of engineered T-cell therapies, such as chimeric antigen receptor T-cell therapy, illustrate the growing feasibility and impact of these approaches across oncology, hematology, and emerging non-malignant indications. Despite remarkable progress, significant barriers continue to limit broader implementation of gene therapy. Immunogenicity to viral vectors and transgene products, manufacturing complexity, scalability constraints, long-term safety monitoring requirements, and unprecedented treatment costs remain critical challenges. The economic burden associated with gene therapies necessitates innovative reimbursement models and policy frameworks to ensure sustainability and equitable access. Ethical considerations, including informed consent, long-term risk assessment, and governance of genome editing technologies, are increasingly central as gene therapy expands to more common and complex diseases. Gene therapy now represents a diverse and rapidly evolving ecosystem of therapeutic platforms rather than a single technological approach. Continued innovation in delivery systems, genome editing precision, manufacturing processes, and regulatory frameworks will be essential to fully realize it's potential. As integration into routine clinical practice accelerates, multidisciplinary collaboration, rigorous long-term surveillance, and responsible ethical oversight will be critical to ensuring that gene therapy fulfills its promise as a cornerstone of precision and personalized medicine. Gene therapy has emerged as a transformative paradigm in modern biomedical science, fundamentally redefining approaches to disease treatment by targeting underlying genetic and molecular mechanisms rather than solely managing clinical symptoms. Over the past four decades, advances in molecular biology, virology, genome engineering, and translational medicine have driven the evolution of gene therapy from an experimental concept to a clinically validated therapeutic modality with multiple regulatory approvals and expanding indications. This comprehensive review critically examines the scientific foundations, technological breakthroughs, clinical achievements, and persistent challenges shaping the contemporary gene therapy landscape. The gene therapy now represents a diverse and rapidly evolving ecosystem of therapeutic platforms rather than a single technological approach. Continued

innovation in delivery systems, genome editing precision, manufacturing processes, and regulatory frameworks will be essential to fully realize it's potential. As integration into routine clinical practice accelerates, multidisciplinary collaboration, rigorous long-term surveillance, and responsible ethical oversight will be critical to ensuring that gene therapy fulfills its promise as a cornerstone of precision and personalized medicine.
Keywords: Gene therapy, viral vectors, Genome editing; CRISPR-Cas systems, precision medicine.

Background

Gene therapy has emerged as one of the most transformative innovations in modern biomedical science, redefining the conceptual foundations of disease treatment by targeting pathophysiology at the genetic and molecular levels rather than focusing solely on symptomatic management. The fundamental premise of gene therapy involves the deliberate modification of genetic material within a patient's cells to correct, compensate for, or modulate disease-causing biological processes. This paradigm shift represents a departure from traditional pharmacotherapy, which typically requires chronic administration of small-molecule drugs or biologics to control disease manifestations without altering the underlying genetic determinants. Over the past four decades, gene therapy has evolved from a speculative experimental concept into a clinically validated therapeutic strategy with multiple regulatory approvals, expanding indications, and demonstrable long-term benefits across a growing range of diseases.

The origins of gene therapy can be traced to the rapid advances in molecular biology and recombinant DNA technology during the latter half of the twentieth century. The elucidation of DNA structure, the genetic code, and mechanisms of gene regulation provided the intellectual framework necessary to envision therapeutic gene manipulation. Early experimental work demonstrated that exogenous genetic material could be introduced into mammalian cells and expressed in a biologically meaningful manner, laying the groundwork for translational applications. By the late 1980s, the convergence of virology, molecular genetics, and immunology enabled the first clinical attempts at gene transfer in humans, marking the beginning of a new era in experimental medicine.

The initial phase of gene therapy development was characterized by cautious optimism, tempered by limited efficacy and significant safety concerns. Early clinical trials primarily focused on monogenic disorders, where replacement of a single defective gene offered a theoretically straightforward therapeutic approach. However, these studies revealed substantial challenges related to inefficient gene delivery, transient expression, immune responses to viral vectors, and unintended genomic effects. High-profile adverse events underscored the risks associated with early-generation vectors and highlighted the need for more sophisticated delivery systems, rigorous regulatory oversight, and a deeper understanding of host–vector interactions. These setbacks, while slowing clinical progress, catalyzed critical scientific and regulatory reforms that ultimately strengthened the field.

A pivotal turning point in gene therapy occurred with the refinement of viral vector technologies, particularly adeno-associated virus and lentiviral systems. Adeno-associated virus vectors demonstrated favorable safety profiles, low pathogenicity, and the capacity for sustained gene expression in non-dividing cells, making them particularly suitable for in vivo applications targeting organs such as the liver, retina, muscle, and central nervous system. In parallel, lentiviral vectors enabled stable genomic integration in dividing cells, facilitating ex vivo modification of hematopoietic stem cells and immune cells. These technological advances addressed many of the limitations encountered in early trials and provided reliable platforms for clinical translation.

The maturation of vector technology coincided with significant progress in manufacturing science and regulatory frameworks. The establishment of good manufacturing practice standards for gene therapy products ensured consistency, safety, and quality across clinical programs. Regulatory agencies developed specialized guidelines recognizing the unique characteristics of gene and cell therapies, including long-term follow-up requirements and adaptive approval pathways for rare and life-threatening conditions. These developments created an environment conducive to innovation while maintaining patient safety, enabling the first wave of regulatory approvals that validated gene therapy as a legitimate clinical modality.

The approval of in vivo gene therapies for inherited retinal dystrophies and neuromuscular disorders marked a milestone in the field, demonstrating that single-administration genetic interventions could produce durable functional improvements. These successes provided proof that targeted gene delivery could restore or compensate for lost biological functions in human tissues. Similarly, ex vivo gene therapy approaches for inherited blood disorders established that autologous genetically modified cells could engraft, persist, and confer long-term clinical benefit. Collectively, these achievements transformed gene therapy from a niche experimental strategy into a cornerstone of precision medicine.

A further acceleration in the field was driven by the advent of genome editing technologies, most notably CRISPR-Cas systems. Unlike traditional gene addition approaches, genome editing enables precise modification of endogenous DNA sequences, allowing direct correction of pathogenic mutations or targeted disruption of disease-associated genes. The relative simplicity, efficiency, and versatility of CRISPR technology revolutionized genetic engineering and rapidly transitioned from basic research laboratories to clinical development. The approval of the first CRISPR-based therapy represented a historic milestone, signaling the clinical feasibility of targeted genome editing and expanding the therapeutic scope of gene therapy.

Alongside genome editing, engineered cell therapies have become a dominant force within the gene therapy landscape. Chimeric antigen receptor T-cell therapy exemplifies the successful integration of genetic engineering with immunotherapy. By reprogramming a patient's own T lymphocytes to recognize and eliminate diseased cells, CAR-T therapy has achieved unprecedented response rates in certain hematological malignancies. The

durability of responses observed in treated patients has challenged conventional notions of cancer therapy and underscored the potential of genetically engineered cells as living drugs. Ongoing refinements in receptor design, cell manufacturing, and toxicity management continue to broaden the applicability of this approach.

The expansion of gene therapy beyond rare monogenic diseases into more common and complex conditions represents a critical evolution of the field. Advances in delivery systems, gene regulation, and editing precision have enabled exploration of gene-based interventions for cardiovascular disease, metabolic disorders, autoimmune diseases, and neurodegenerative conditions. These efforts reflect growing confidence in the safety and efficacy of gene therapy platforms, as well as recognition of their potential to address unmet medical needs on a broader population scale. However, this expansion also introduces new ethical, economic, and clinical considerations, particularly when applying irreversible genetic interventions to diseases with variable severity or multifactorial etiology.

Economic and access considerations have emerged as central challenges in the gene therapy era. The high cost of development, manufacturing complexity, and limited patient populations for many indications have resulted in unprecedented pricing for approved therapies. While long-term cost-effectiveness analyses often support the value of potentially curative treatments, the substantial upfront financial burden poses challenges for healthcare systems, insurers, and patients. Innovative reimbursement models, including outcomes-based payments and annuity-style financing, have been proposed to reconcile innovation with affordability. Addressing these economic barriers is essential to ensure equitable access and prevent widening disparities in healthcare delivery.

Immunological factors remain a critical determinant of gene therapy success. Host immune responses to vectors, transgene products, or edited cells can limit efficacy, restrict re-dosing, or cause adverse effects. Advances in vector engineering, immune modulation strategies, and patient selection criteria have mitigated some of these challenges, but immunogenicity continues to influence therapeutic outcomes. A deeper understanding of immune tolerance mechanisms and the development of less immunogenic delivery systems will be essential for expanding the range of treatable patients and indications.

Ethical considerations also play a prominent role in shaping the future of gene therapy. Issues related to informed consent, long-term risk, intergenerational effects, and equitable access require careful deliberation by clinicians, researchers, regulators, and society at large. While current clinical applications focus on somatic gene therapy, ongoing debates surrounding germline editing highlight the need for clear ethical boundaries and international consensus. Transparent communication, patient engagement, and responsible governance are fundamental to maintaining public trust in genetic medicine.

From a clinical perspective, the integration of gene therapy into routine medical practice necessitates multidisciplinary collaboration and specialized expertise. The administration and monitoring of gene and cell therapies require coordinated efforts among physicians, pharmacists, geneticists, immunologists, and allied healthcare professionals. Education and

training programs must evolve to equip healthcare providers with the knowledge and skills required to manage these complex therapies safely and effectively. In parallel, healthcare infrastructure must adapt to support specialized manufacturing, storage, administration, and long-term follow-up requirements.

In the broader context of biomedical innovation, gene therapy exemplifies the convergence of multiple scientific disciplines, including molecular biology, bioengineering, computational science, and clinical medicine. Advances in bioinformatics and artificial intelligence are increasingly applied to vector design, target identification, and prediction of off-target effects, further accelerating development timelines. These integrative approaches are expected to enhance precision, reduce risk, and enable personalized therapeutic strategies tailored to individual genetic profiles.

The Renaissance: Technological Breakthroughs Enabling Clinical Success

The gene therapy field experienced a renaissance beginning in the late 2000s and accelerating through the 2010s, driven by convergent technological innovations that addressed earlier limitations. The development and refinement of adeno-associated virus vectors represented a crucial advance, offering significant advantages over earlier retroviral and adenoviral platforms. AAV vectors demonstrated favorable safety profiles with minimal immunogenicity, broad tissue tropism through diverse natural serotypes and engineered variants, and the capacity to transduce both dividing and post-mitotic cells. Critically, AAV vectors predominantly remained episomal rather than integrating into the host genome, substantially reducing insertional mutagenesis risks. The small size of AAV virions facilitated manufacturing scale-up, while the existence of multiple serotypes with distinct tissue tropisms enabled targeted delivery to specific organs including liver, muscle, retina, and central nervous system.

The engineering of self-inactivating lentiviral vectors derived from human immunodeficiency virus type 1 provided another critical technological advancement for ex vivo gene therapy applications. Unlike earlier gamma-retroviral vectors, lentiviral vectors could transduce non-dividing cells and demonstrated reduced genotoxicity due to different integration site preferences, favoring gene bodies over promoter regions. The incorporation of safety modifications including deletion of viral regulatory elements, separation of packaging components across multiple plasmids, and replacement of the viral envelope with vesicular stomatitis virus G protein enhanced biosafety profiles. These improvements made lentiviral vectors the preferred platform for ex vivo transduction of hematopoietic stem cells and T lymphocytes, enabling successful development of CAR-T cell therapies and gene-corrected stem cell treatments for blood disorders and lysosomal storage diseases.

The discovery and adaptation of CRISPR-Cas9 gene editing technology represented perhaps the most transformative innovation in modern molecular biology, fundamentally expanding gene therapy capabilities beyond simple gene addition. Adapted from a bacterial

adaptive immune system, CRISPR-Cas9 enables precise, targeted modifications at specific genomic loci through programmable guide RNAs directing the Cas9 nuclease to complementary DNA sequences. This technology enables diverse genetic modifications including gene knockout through non-homologous end joining, precise correction through homology-directed repair, and base-level changes through fusion with deaminase enzymes. The simplicity, versatility, and efficiency of CRISPR editing democratized genome engineering and enabled applications previously impossible with earlier technologies such as zinc finger nucleases and transcription activator-like effector nucleases. The rapid translation of CRISPR technology from basic research tool to therapeutic modality, exemplified by the approval of Casgevy less than twelve years after the technology's initial description, represents an unprecedented pace of clinical development.

Concurrent advances in cell therapy manufacturing, including development of closed automated processing systems, implementation of good manufacturing practice protocols for cell manipulation, and optimization of cryopreservation methods, enabled scalable production of engineered cell products. The establishment of specialized manufacturing facilities, development of supply chain logistics for temperature-sensitive biological products, and creation of quality control assays for characterizing genetically modified cells transformed autologous cell therapy from small-scale academic exercises to commercially viable therapeutic products. These manufacturing innovations proved essential for CAR-T cell therapy development, enabling consistent production of complex cellular products meeting regulatory standards for safety, purity, and potency.

Viral Vector Platforms: AAV and Lentiviral Systems

Adeno-associated virus vectors have emerged as the dominant platform for in vivo gene therapy due to favorable biological properties and clinical track record. AAV is a small, non-enveloped virus naturally infecting humans but not causing known disease, making it an attractive therapeutic vector with inherent low pathogenicity. The discovery that AAV vectors primarily remain episomal in transduced cells rather than integrating into chromosomes substantially reduces genotoxicity risks compared to integrating vectors, though rare integration events can occur. The existence of numerous natural AAV serotypes with distinct tissue tropisms, determined by differences in capsid proteins dictating cell surface receptor interactions, enables targeted gene delivery to specific organs. AAV2 demonstrates efficient transduction of retinal pigment epithelium and photoreceptors, making it ideal for ocular gene therapy as demonstrated by Luxturna. AAV8 and AAV9 show strong hepatic tropism enabling treatment of liver-directed disorders including hemophilia, while AAV9 crosses the blood-brain barrier allowing central nervous system gene delivery.

The clinical development of AAV gene therapies has validated efficacy across diverse diseases while revealing important limitations requiring ongoing innovation. Multiple

AAV-based hemophilia gene therapies have demonstrated sustained factor VIII or factor IX expression following single intravenous vector administration, achieving near-normalization of clotting factor levels in many patients and dramatically reducing bleeding episodes and factor replacement requirements (Kumar et al., 2016). Durability data extending beyond five years for some products demonstrate stable transgene expression, suggesting potential for lifelong therapeutic benefit from single treatment. However, progressive decline in transgene expression observed in some patients, attributed to immune-mediated clearance of transduced hepatocytes, highlights the need for strategies enhancing long-term expression including immunosuppression protocols and novel promoter designs.

Pre-existing neutralizing antibodies against AAV capsids represent a significant limitation, rendering 30-50% of the population ineligible for treatment depending on serotype and antibody titer thresholds. These antibodies, resulting from natural AAV exposure throughout childhood and adulthood, block vector transduction by preventing cellular uptake or promoting vector clearance. While patient screening enables identification of antibody-negative individuals suitable for treatment, the substantial proportion of excluded patients motivated development of strategies overcoming antibody limitations including plasmapheresis to remove circulating antibodies, use of alternative serotypes with lower seroprevalence, and engineering of capsid variants with altered antigenic profiles. The inability to re-dose with the same serotype due to development of potent neutralizing antibodies following initial vector administration further constrains therapeutic flexibility, though use of different serotypes for subsequent dosing or immunosuppression regimens enabling re-administration represent potential solutions.

Lentiviral vectors have become the preferred platform for ex vivo gene therapy applications requiring stable genomic integration to ensure transgene maintenance through cell division. Derived from HIV-1 but extensively modified for safety, clinical-grade lentiviral vectors lack all viral genes required for replication, utilize heterologous envelope proteins preventing tropism for human cells, and incorporate self-inactivating modifications eliminating transcriptional activity from long terminal repeats. These safety features, combined with the ability to accommodate relatively large transgenes exceeding 8 kilobases and efficiently transduce both dividing and non-dividing cells, make lentiviral vectors particularly suitable for hematopoietic stem cell gene therapy and CAR-T cell manufacturing. The use of lentiviral vectors in multiple approved products including Casgevy, Lyfgenia, and all commercial CAR-T therapies demonstrates their clinical viability and regulatory acceptance.

Clinical Success in Monogenic Blood Disorders

Monogenic blood disorders affecting hematopoietic lineages represent an optimal initial target for gene therapy due to accessible target tissues, well-characterized disease genetics,

established transplantation expertise enabling engraftment of gene-modified cells, and severe disease burden justifying innovative therapeutic approaches. Sickle cell disease, caused by a single point mutation in the beta-globin gene resulting in production of abnormal hemoglobin that polymerizes under deoxygenated conditions causing erythrocyte sickling, affects approximately 100,000 individuals in the United States and millions globally, predominantly among populations of African, Mediterranean, and Middle Eastern ancestry. The disease manifests through recurrent painful vaso-occlusive crises, progressive organ damage, increased infection susceptibility, and reduced life expectancy. While hematopoietic stem cell transplantation can cure sickle cell disease, donor availability limitations and transplant-related risks including graft failure and chronic graft-versus-host disease restrict this option to a minority of patients.

Gene therapy approaches for sickle cell disease have pursued two primary strategies: addition of a functional beta-globin or anti-sickling beta-globin variant to overcome the defective endogenous gene, or reactivation of fetal hemoglobin expression which naturally ameliorates disease manifestations. Lyfgenia employs a lentiviral vector encoding a modified beta-globin gene (beta-A-T87Q-globin) with increased anti-sickling properties, transducing autologous CD34-positive hematopoietic stem cells ex vivo before reinfusion following myeloablative conditioning (Rahmat et al., 2024). Clinical trial results demonstrated that vector-derived anti-sickling hemoglobin comprised 20-40% of total hemoglobin in most patients, sufficient to eliminate or dramatically reduce vaso-occlusive crises and enable discontinuation of chronic transfusion therapy in the majority of treated individuals. Long-term follow-up through three years post-treatment shows maintained therapeutic hemoglobin levels and sustained clinical benefits in most patients.

Casgevy represents an alternative approach employing CRISPR-Cas9 editing to disrupt the BCL11A erythroid-specific enhancer in hematopoietic stem cells, leading to reactivation of fetal hemoglobin production. BCL11A is a transcriptional repressor that normally silences fetal hemoglobin genes during the transition from fetal to adult erythropoiesis; disruption of its erythroid-specific enhancer preserves BCL11A function in other cell types while specifically reducing expression in red blood cell precursors, enabling fetal hemoglobin reactivation (Singh et al., 2024). Clinical trials demonstrated that Casgevy-treated patients achieved fetal hemoglobin levels of 30-40% of total hemoglobin, with complete elimination of vaso-occlusive crises in the majority of sickle cell disease patients throughout follow-up periods extending beyond two years. The therapy also demonstrated efficacy in transfusion-dependent beta thalassemia, another hemoglobinopathy characterized by deficient beta-globin production, with most treated patients achieving transfusion independence.

Hemophilia A and B, X-linked bleeding disorders caused by deficiency of coagulation factors VIII and IX respectively, have been extensively targeted by AAV gene therapy approaches delivering functional factor genes to hepatocytes for sustained protein production. The liver represents an ideal target tissue for hemophilia gene therapy due to its natural role in producing coagulation factors, efficient transduction by AAV vectors,

relatively immunologically privileged environment, and large reserve capacity allowing therapeutic benefit from transduction of only a fraction of hepatocytes. Multiple hemophilia B gene therapy products have demonstrated that single intravenous AAV vector administration can achieve sustained factor IX expression at levels converting severe hemophilia (factor levels less than 1% of normal) to mild phenotype (factor levels 5-40% of normal), dramatically reducing bleeding episodes and eliminating or substantially reducing the need for prophylactic factor replacement infusions. Beqvez, approved in 2024, demonstrated mean factor IX activity of approximately 36% of normal at one-year post-treatment, with sustained expression through multi-year follow-up in most patients and elimination of bleeding episodes in the majority.

Challenges and Barriers to Broader Implementation

Despite remarkable scientific and clinical progress, gene therapy faces substantial challenges that limit broader patient access and therapeutic application across diverse diseases. Economic factors represent perhaps the most significant barrier, with approved gene therapies priced between $400,000 and $4.25 million per treatment, reflecting high development costs, complex manufacturing requirements, small patient populations for rare disease indications, and pharmaceutical industry pricing strategies. While health economic analyses often conclude that single-administration curative therapies represent good value compared to lifelong conventional treatments when assessed over patient lifetimes, the concentrated upfront costs create significant budget impact challenges for healthcare payers and threaten to overwhelm healthcare system resources if gene therapy utilization scales substantially. The tension between recognizing gene therapy's transformative potential and constraining healthcare expenditure growth has generated intense debate regarding appropriate pricing frameworks, reimbursement models, and societal willingness to pay for potentially curative treatments.

Manufacturing complexities and capacity limitations represent additional critical barriers, particularly for autologous cell therapies requiring individualized production for each patient. CAR-T cell manufacturing involves multiple technically demanding steps including patient leukapheresis, cell activation and transduction with viral vectors, expansion culture under tightly controlled conditions, extensive quality control testing, formulation, cryopreservation, and distribution to treatment centers, requiring approximately 2-4 weeks and sophisticated facilities meeting good manufacturing practice standards. Manufacturing failures occur in 2-10% of cases depending on product and patient characteristics, necessitating restart of the process and delaying treatment for rapidly progressing patients. The current centralized manufacturing model, with most production occurring at a limited number of specialized facilities, creates logistical challenges and limits treatment capacity. Alternative approaches under development include point-of-care manufacturing enabling production at treatment centers, automation technologies reducing

hands-on manipulation and potential for contamination, and off-the-shelf allogeneic products eliminating individualized manufacturing requirements but facing their own challenges related to immune rejection and limited persistence.

Immunogenicity issues affecting both vector components and transgene products can limit therapeutic efficacy and create safety concerns. Pre-existing neutralizing antibodies to AAV capsids, present in 30-50% of the population depending on serotype, preclude treatment of substantial patient fractions. Even in antibody-negative individuals, vector administration triggers adaptive immune responses generating high-titer neutralizing antibodies that prevent re-dosing with the same serotype. Cellular immune responses directed against AAV capsid peptides presented on transduced cells can mediate clearance of transduced cells and loss of transgene expression, as observed in some hemophilia gene therapy trials where factor levels declined months after initial therapeutic levels were achieved. Immunosuppression protocols initiated at the time of vector administration may mitigate these responses but add complexity and potential toxicity. Immune responses against transgene products represent another concern, particularly in patients with severe mutations resulting in complete absence of the native protein, who may recognize the gene therapy-produced protein as foreign and mount antibody responses neutralizing therapeutic benefit.

Long-term safety surveillance requirements and ongoing questions about potential late-emerging risks necessitate extended follow-up extending 15 years post-treatment for gene therapies involving genomic modification, creating substantial logistical and financial burdens for developers and patients. While no late-emerging safety signals have appeared in most gene therapy programs with extended follow-up, the theoretical potential for delayed adverse events including insertional mutagenesis leading to cancer, late-onset immune responses, or unexpected off-target effects from gene editing maintain the need for vigilant long-term monitoring. The development of registry systems and streamlined follow-up procedures aim to minimize patient burden while maintaining safety oversight but ensuring high rates of long-term follow-up completion remains challenging as patients appropriately prioritize resuming normal lives after successful treatment over continued clinical visits and testing.

Discussion

The rapid maturation of gene therapy represents one of the most consequential paradigm shifts in contemporary biomedical science, redefining therapeutic strategy by directly addressing disease causation at the genomic and molecular levels. The findings and developments synthesized in this review collectively demonstrate that gene therapy has transitioned from experimental novelty to a clinically actionable and increasingly standardized modality. This transition reflects not only technological innovation but also a deeper understanding of disease biology, immune regulation, manufacturing science, and

regulatory governance. Importantly, the present era of gene therapy is characterized not by a single dominant technology but by a diversified portfolio of platforms tailored to specific biological contexts and therapeutic objectives.

One of the most significant insights emerging from recent clinical experience is that successful gene therapy depends fundamentally on the alignment between disease biology and therapeutic modality. Monogenic disorders affecting accessible or renewable tissues, such as hematopoietic stem cells, hepatocytes, and retinal cells, have proven most amenable to early gene therapy success. In these settings, partial restoration of protein function often yields disproportionate clinical benefit, allowing therapeutic efficacy even when transgene expression does not fully replicate physiological levels. This principle has been clearly demonstrated in hemophilia, sickle cell disease, and inherited retinal dystrophies, where modest genetic correction produces dramatic improvements in quality of life and disease burden. These successes underscore the importance of strategic disease selection and biological feasibility in gene therapy development.

Viral vector–mediated gene delivery, particularly using adeno-associated virus and lentiviral systems, remains the backbone of current clinical gene therapy. AAV-based in vivo therapies have established a strong safety and efficacy profile, especially in non-dividing tissues, validating episomal persistence as a viable strategy for long-term therapeutic expression. However, emerging data also highlight intrinsic limitations of AAV platforms, including packaging size constraints, susceptibility to pre-existing neutralizing antibodies, and challenges related to re-dosing. These limitations suggest that while AAV vectors will continue to dominate certain therapeutic areas, they are unlikely to represent a universal solution. Continued capsid engineering, serotype diversification, and immune evasion strategies will be necessary to extend AAV applicability to broader patient populations and disease indications.

Lentiviral vectors, by contrast, have demonstrated particular strength in ex vivo applications requiring stable genomic integration and long-term expression through cell division. Their success in hematopoietic stem cell modification and CAR-T cell therapy illustrates how controlled integration, when combined with improved vector design and rigorous safety testing, can yield durable benefit with acceptable risk. Nevertheless, integration-associated genotoxicity, although substantially mitigated compared to earlier retroviral systems, remains a theoretical concern requiring long-term surveillance. The balance between therapeutic durability and genomic safety continues to shape vector choice and clinical decision-making, particularly as genome editing technologies offer alternative routes to stable genetic correction without reliance on random integration.

The emergence of CRISPR-based genome editing represents a conceptual inflection point in gene therapy, shifting the field from gene supplementation toward precise genetic repair. Unlike traditional gene addition approaches, genome editing enables modification of endogenous loci, preserving physiological gene regulation and minimizing risks associated with ectopic expression. Clinical validation of CRISPR-based therapies for

hemoglobinopathies has demonstrated that targeted disruption of regulatory elements can achieve therapeutic outcomes comparable to gene replacement while potentially offering improved durability. These successes also illustrate the power of leveraging developmental biology, such as fetal hemoglobin reactivation, to achieve therapeutic benefit without direct correction of disease-causing mutations.

Despite its transformative potential, genome editing introduces novel challenges that distinguish it from earlier gene therapy paradigms. Off-target effects, unintended genomic rearrangements, and immune responses to bacterial-derived nucleases necessitate rigorous preclinical validation and conservative clinical implementation. The development of base editors and prime editors reflects an ongoing effort to refine editing precision while minimizing genotoxic risk. However, clinical translation of these next-generation tools will require careful assessment of editing efficiency, delivery feasibility, and long-term safety, particularly for in vivo applications where reversibility is not possible. As genome editing technologies evolve, their integration into clinical practice will demand heightened ethical scrutiny and regulatory oversight.

Engineered cell therapies, particularly CAR-T cells, represent one of the most clinically impactful applications of gene therapy to date. Their success challenges traditional pharmacological models by introducing living, self-amplifying therapeutic agents capable of long-term persistence and dynamic response to disease. The durability of remission observed in certain hematological malignancies suggests that gene-modified immune cells can function as autonomous therapeutic systems rather than transient interventions. However, CAR-T therapy also exemplifies the complexity of translating gene therapy into routine clinical practice, given its association with unique toxicities, individualized manufacturing requirements, and substantial cost. Expanding CAR-T approaches to solid tumors and non-oncologic indications will require further advances in target selection, cell engineering, and safety management.

Manufacturing science has emerged as a central determinant of gene therapy accessibility and scalability. The individualized nature of autologous cell therapies and the technical complexity of viral vector production impose significant logistical and economic constraints. Current manufacturing paradigms, while effective for limited patient populations, are unlikely to sustain widespread adoption without substantial innovation. Automation, standardization, and decentralization of manufacturing processes represent critical priorities for the field. Moreover, manufacturing reliability directly influences clinical outcomes, as delays or failures can be life-threatening for patients with rapidly progressing disease. Thus, manufacturing should be viewed not merely as a technical consideration but as an integral component of therapeutic efficacy.

Economic considerations increasingly shape the gene therapy discourse, particularly as approved products command unprecedented prices. While long-term cost-effectiveness analyses often support the value of potentially curative therapies, the upfront financial burden poses systemic challenges for healthcare systems. This tension highlights a

fundamental misalignment between traditional reimbursement models and the economic reality of one-time, high-impact treatments. Outcomes-based payment structures, risk-sharing agreements, and annuity-style reimbursement models represent promising approaches to reconciling innovation with affordability. However, their implementation requires coordination among manufacturers, payers, regulators, and clinicians, as well as robust data infrastructure to track long-term outcomes.

Ethical and societal considerations are inseparable from the scientific evolution of gene therapy. As interventions become more permanent and potentially heritable in effect, the responsibility to ensure informed consent, transparency, and equitable access becomes paramount. Although current clinical applications are limited to somatic gene therapy, public concern regarding germline modification underscores the need for clear ethical boundaries and international consensus. Furthermore, disparities in access to gene therapy, both within and between countries, risk exacerbating existing health inequities if not proactively addressed. Ensuring that gene therapy advances benefit diverse populations requires deliberate policy planning, global collaboration, and investment in healthcare infrastructure.

Regulatory frameworks have evolved in response to the unique characteristics of gene therapy, adopting adaptive pathways that balance early access with safety oversight. Accelerated approval mechanisms, acceptance of surrogate endpoints, and platform-based regulatory approaches reflect recognition that traditional drug development models are ill-suited to rare and life-threatening genetic diseases. Nevertheless, regulatory flexibility must be accompanied by rigorous post-marketing surveillance to identify late-emerging risks and ensure long-term patient safety. The requirement for extended follow-up underscores the enduring responsibility of developers and healthcare systems to patients receiving irreversible genetic interventions.

From a translational perspective, the success of gene therapy underscores the importance of multidisciplinary collaboration. Effective development and clinical implementation require integration of molecular biology, immunology, clinical medicine, pharmacy, bioinformatics, ethics, and health economics. Pharmacists and clinical pharmacologists, in particular, play an increasingly important role in gene therapy administration, monitoring, and patient education, reflecting the convergence of pharmacotherapy and genetic medicine. Education and training programs must evolve accordingly to prepare healthcare professionals for this new therapeutic landscape.

Looking forward, the future of gene therapy will likely be defined by convergence rather than competition among platforms. Hybrid approaches combining viral delivery, genome editing, and cell engineering may achieve therapeutic outcomes unattainable by any single modality. Advances in artificial intelligence and computational biology are expected to accelerate vector design, target identification, and risk prediction, further enhancing precision and safety. As these innovations unfold, the central challenge will be to translate

technological capability into real-world benefit while maintaining ethical integrity, economic sustainability, and patient-centered care.

Gene therapy stands at a pivotal juncture, having demonstrated undeniable clinical value while confronting complex challenges that will shape its trajectory for decades to come. The evidence reviewed herein supports cautious optimism that continued scientific innovation, coupled with thoughtful regulatory and policy frameworks, will enable gene therapy to fulfill its promise as a cornerstone of precision medicine. The task ahead lies not only in advancing technology but in ensuring that its benefits are delivered safely, equitably, and responsibly to patients worldwide.

Therapeutic Platform Maturation and Diversification

The current gene therapy landscape encompasses diverse technological platforms, each with distinct advantages, limitations, and optimal applications, reflecting the field's maturation beyond singular approaches toward selection of modality best suited to specific therapeutic objectives. Viral vector-based gene addition therapies, particularly those employing AAV vectors, have established strong clinical track records in applications requiring sustained transgene expression in post-mitotic tissues including liver, muscle, retina, and central nervous system. The demonstration that single AAV vector administration can achieve multi-year transgene expression sufficient to convert severe hemophilia to mild phenotype validates this approach for protein replacement applications where precise expression level control is not critical and modest protein levels provide substantial clinical benefit. However, AAV vector limitations including packaging size constraints restricting transgene length to approximately 4.7 kilobases, pre-existing neutralizing antibodies limiting eligible patient populations, and potential immune-mediated transgene expression loss highlight the need for continued platform refinement and alternative approaches.

CRISPR-based gene editing offers fundamentally different capabilities including permanent correction of pathogenic mutations at their genomic locations, targeted gene disruption for loss-of-function therapeutic effects, and precise insertion of therapeutic sequences into safe harbor loci enabling sustained expression without reliance on episomal vector persistence. The approval of Casgevy demonstrates clinical viability of ex vivo CRISPR editing, while early-phase trials of in vivo editing delivered via lipid nanoparticles establish proof-of-concept for direct tissue editing. The development of base editors and prime editors, enabling nucleotide-level changes without double-strand break formation, addresses safety concerns regarding unintended chromosomal rearrangements and represents the next generation of editing tools likely to enter clinical trials in the coming years. However, CRISPR technology faces its own challenges including potential off-target editing at genomic sites with partial guide RNA complementarity, limited editing efficiency in non-

dividing cells for some delivery methods, and immunogenicity of Cas9 protein derived from bacterial species to which humans have prior immune exposure.

CAR-T cell therapy represents perhaps the most clinically advanced gene therapy modality, with seven FDA-approved products and expanding applications beyond initial hematological malignancy indications. The dramatic complete response rates achieved in relapsed/refractory B-cell lymphomas and acute lymphoblastic leukemia, coupled with long-term follow-up data demonstrating durable remissions in substantial patient fractions, establish CAR-T therapy as a curative option for diseases previously uniformly fatal. The recent expansion into T-cell receptor therapy with Tecelra's approval for synovial sarcoma and tumor-infiltrating lymphocyte therapy with Amtagvi's approval for melanoma demonstrates continued innovation in engineered cell therapy approaches. The preliminary success of CAR-T therapy in autoimmune disorders including systemic lupus erythematosus and myasthenia gravis suggests potential for transformative impact beyond oncology, though larger controlled trials are required to establish optimal protocols and define patient populations most likely to benefit.

The integration of multiple technological platforms within comprehensive therapeutic strategies represents an emerging trend likely to accelerate as the field matures. Combination approaches might include AAV-delivered base editors enabling precise in vivo editing with reduced immunogenicity compared to protein-based editor delivery, CAR-T cells engineered with CRISPR to enhance function or reduce exhaustion, or sequential administration of different modalities addressing complementary aspects of disease pathology. The development of switchable or tunable gene expression systems responsive to exogenous small molecules offers potential for post-administration control over transgene activity, addressing safety concerns related to excessive or inappropriate expression. These sophisticated approaches leverage the strengths of individual platforms while mitigating their limitations, potentially achieving therapeutic effects unattainable with single-modality interventions.

Manufacturing Innovation as Critical Enabler

Manufacturing capability represents a critical determinant of gene therapy accessibility, with current production limitations constraining the number of patients who can receive treatment regardless of clinical efficacy or regulatory approval status. Autologous cell therapies face particular challenges, requiring individualized manufacturing for each patient with timelines typically spanning 2-4 weeks from cell collection to product delivery (Lu and Jiang, 2022). The complex multi-step process including cell activation, viral transduction, culture expansion, quality control testing, formulation, and cryopreservation demands specialized facilities, highly trained personnel, and sophisticated quality systems ensuring product consistency and safety. Manufacturing failures, occurring in 2-10% of cases due to inadequate cell collection, failed transduction, contamination, or cells not

meeting release specifications, necessitate process restarts and impose substantial delays for patients with aggressive diseases. The current centralized manufacturing model, with most production concentrated at limited numbers of specialized contract manufacturing organizations, creates capacity bottlenecks and logistical complexity coordinating patient material shipment, production scheduling, and finished product delivery.

Several innovative approaches aim to address manufacturing limitations and enhance scalability. Closed automated manufacturing systems reduce hands-on manipulation requirements, minimize contamination risks, improve process consistency, and potentially enable distributed manufacturing at treatment centers rather than centralized facilities. The Cocoon and Xuri platforms represent examples of closed automated systems under development or in use for CAR-T manufacturing, potentially enabling point-of-care production reducing logistics complexity and treatment timelines. Allogeneic off-the-shelf cell therapy products manufactured from healthy donor cells in large batches, then cryopreserved for on-demand availability, eliminate patient-specific manufacturing requirements and associated delays, though they require strategies addressing immune rejection including HLA matching or engineering of universal donor cells through CRISPR-mediated disruption of HLA genes and other immunogenicity determinants. Early clinical trials of allogeneic CAR-T products demonstrate proof-of-concept feasibility, though persistence and efficacy appear reduced compared to autologous products, motivating continued optimization.

For viral vector-based therapies, manufacturing scale-up to meet potential demand for common disease applications presents different challenges. Current AAV production predominantly employs transient transfection of adherent HEK293 cells, a process suitable for small to moderate production volumes but challenging to scale to the levels required for treating large patient populations. The transition to suspension-adapted cell lines enables bioreactor-based production with substantially increased volumetric yields and improved scalability. Alternative production platforms including baculovirus-insect cell systems and herpes simplex virus complementation systems offer different advantages regarding yield, purity, and manufacturing complexity. Downstream purification processes removing empty capsids, host cell proteins, and residual DNA represent another critical aspect requiring optimization to achieve the purity levels necessary for large-dose systemic administration. The substantial costs associated with viral vector manufacturing, ranging from hundreds of thousands to millions of dollars per patient dose depending on vector dose and production scale, contribute significantly to overall gene therapy pricing and represent a key target for cost reduction efforts.

Quality control and characterization of gene therapy products present unique challenges compared to conventional pharmaceuticals due to biological complexity and product heterogeneity. CAR-T products comprise mixed cell populations with varying phenotypes, transduction efficiencies, and functional capabilities requiring multiple orthogonal assays to adequately characterize identity, purity, potency, and safety. Vector preparations require

assessment of physical titer, infectious titer, and empty versus full capsid ratios, residual impurities, and adventitious agent testing. The development of rapid, cost-effective analytical methods enabling real-time release testing rather than extended hold times awaiting assay results could substantially reduce treatment timelines. Standardization of potency assays across different products and manufacturing sites remains an ongoing challenge, as functional assessments often demonstrate high variability and limited correlation with clinical outcomes, necessitating continued refinement and validation.

Regulatory Evolution and Adaptive Frameworks

The regulatory landscape for gene therapy has undergone substantial evolution to accommodate the unique characteristics of genetic medicines while maintaining appropriate safety oversight. Traditional drug development paradigms emphasizing large randomized controlled trials establishing safety and efficacy through comparison to standard of care prove challenging for gene therapies targeting rare diseases where patient populations are small, disease heterogeneity is high, and ethical concerns arise regarding randomization to placebo or conventional therapy when gene therapy shows promise in early studies. Regulatory agencies have responded by developing adaptive frameworks including accelerated approval pathways based on surrogate endpoints reasonably likely to predict clinical benefit, acceptance of smaller patient numbers with extended follow-up for rare diseases, and willingness to consider single-arm trials with historical controls for conditions lacking effective treatments.

The FDA's Regenerative Medicine Advanced Therapy designation, established through the 21st Century Cures Act, provides enhanced interaction between sponsors and the agency during development, potential eligibility for priority article and accelerated approval, and access to expedited manufacturing development programs. Similar mechanisms exist in Europe through the PRIME scheme and in other jurisdictions, reflecting global recognition that gene therapy development requires regulatory flexibility while maintaining safety standards. The approval of Casgevy based on approximately 90 treated patients across sickle cell disease and beta thalassemia trials with median follow-up of approximately two years demonstrates regulatory willingness to approve transformative therapies based on smaller datasets than typically required for conventional drugs, accepting greater uncertainty regarding long-term outcomes in exchange for earlier patient access to potentially curative treatments.

Platform technology approaches, where common manufacturing processes and vector systems are adapted for different target genes or disease indications, represent another area of regulatory innovation. The approval in 2025 of a personalized CRISPR therapy developed and delivered within six months for an infant with a unique genetic condition established precedent for rapid development and regulatory authorization of individualized treatments. This approach acknowledges that for ultra-rare genetic variants affecting single or few

patients, conducting traditional clinical trials is impossible, yet patients deserve access to potentially lifesaving therapies. The regulatory framework evaluating platform technology safety and proof-of-concept efficacy, then enabling application to new indications through streamlined processes focusing on indication-specific considerations while relying on platform-level data for general safety assessment, could dramatically accelerate access to gene therapies for the thousands of ultra-rare genetic diseases collectively affecting substantial patient populations but individually too rare for traditional development.

Post-marketing surveillance requirements for gene therapies reflect ongoing uncertainty regarding late-emerging risks including insertional mutagenesis, delayed immune responses, and unexpected off-target effects from gene editing. Regulatory agencies typically require 15-year follow-up for patients receiving gene therapies involving genomic integration or modification, implemented through patient registries collecting standardized data elements. These registries aim to detect safety signals that might emerge with longer follow-up than clinical trial durations while minimizing patient burden through streamlined data collection focused on priority safety endpoints. However, achieving high rates of long-term follow-up completion remains challenging as patients appropriately prioritize resuming normal lives over continued study participation, particularly when feeling well and not experiencing obvious problems. The development of remote monitoring capabilities including patient-reported outcomes collected through smartphone applications and integration with electronic health record systems may enhance follow-up rates while reducing patient burden.

Technical Frontiers: Next-Generation Editing and Delivery

Ongoing technological innovation promises to overcome current gene therapy limitations and enable applications beyond present capabilities. Base editing and prime editing represent next-generation genome modification tools offering enhanced precision compared to conventional CRISPR-Cas9 editing. Base editors comprise catalytically impaired Cas9 variants fused to deaminase enzymes that convert specific nucleotides without creating double-strand breaks, enabling correction of point mutations through C-to-T, A-to-G, or reverse conversions depending on the deaminase employed. This approach addresses safety concerns regarding chromosomal rearrangements and large deletions potentially resulting from double-strand break formation and subsequent error-prone repair. Early preclinical studies demonstrate efficient base editing in multiple therapeutically relevant cell types including hematopoietic stem cells, hepatocytes, and T lymphocytes, with several programs advancing toward clinical trials for diseases including sickle cell disease, familial hypercholesterolemia, and various cancers.

Prime editing represents an even more sophisticated modification approach, employing a catalytically impaired Cas9 fused to reverse transcriptase along with an extended guide RNA encoding both the targeting sequence and a template for the desired modification. This

system enables insertion, deletion, or replacement of DNA sequences up to approximately 80 base pairs without requiring double-strand breaks or separate donor DNA templates. Prime editing theoretically enables correction of the majority of known pathogenic mutations including all classes of point mutations, small insertions and deletions, and even some larger sequence changes, potentially addressing a broader range of genetic diseases than base editors or conventional CRISPR systems. However, prime editing efficiency in primary human cells relevant for therapeutic applications has proven more challenging than in established cell lines, necessitating continued optimization before clinical translation. The combination of prime editing with delivery system innovations may enable in vivo correction of previously intractable disease-causing mutations.

Delivery system development represents another critical frontier, as achieving efficient gene transfer or editing in target tissues while minimizing off-target delivery and toxicity remains challenging for many organs. Lipid nanoparticle delivery systems, validated through COVID-19 mRNA vaccine success, are being optimized for therapeutic applications including CRISPR component delivery for in vivo editing and mRNA delivery for transient protein expression. The development of tissue-specific lipid formulations incorporating targeting ligands that bind receptors enriched on desired cell types aims to enhance delivery specificity, potentially enabling efficient gene transfer to tissues currently difficult to target including lung, heart, and brain. Exosome-based delivery systems utilizing naturally occurring cell-derived vesicles capable of crossing biological barriers and delivering cargo to recipient cells represent another innovative approach under preclinical investigation, potentially offering lower immunogenicity than synthetic delivery vehicles.

AAV capsid engineering through directed evolution and rational design has generated variants with enhanced properties including improved transduction efficiency, altered tissue tropism, reduced antibody neutralization, and decreased immunogenicity. High-throughput screening approaches evaluating large capsid variant libraries in relevant disease models enable identification of variants with desired characteristics. Several engineered AAV variants have advanced to clinical trials, including capsids selected for enhanced central nervous system transduction following systemic administration, potentially enabling treatment of neurodegenerative diseases without requiring direct brain injection. The discovery that some engineered capsids demonstrate reduced neutralization by antibodies against natural serotypes suggests possibility of treating seropositive patient populations currently excluded from AAV gene therapy, substantially expanding eligible populations if confirmed in clinical trials.

Lessons from Clinical Translation and Remaining Questions

The successful clinical translation of multiple gene therapy modalities from preclinical concept to approved products provides valuable lessons applicable to ongoing development programs and future innovations. The importance of robust preclinical studies in disease-

relevant animal models, including large animal models with anatomy and physiology more closely approximating humans, has been repeatedly demonstrated. Early gene therapy failures partly resulted from inadequate preclinical characterization of immune responses and toxicities that manifested differently in human patients compared to small animal models. Contemporary development programs incorporate extensive toxicology studies in non-human primates evaluating dose-dependent effects, comprehensive biodistribution analyses determining vector distribution across tissues, and immunogenicity assessments characterizing both cellular and humoral responses. While these studies increase development timelines and costs, they provide critical safety data informing starting doses, monitoring strategies, and risk mitigation approaches for first-in-human trials.

The selection of appropriate initial disease targets represents another critical success factor, with most successful gene therapy programs initially targeting monogenic disorders affecting accessible tissues with validated animal models and significant unmet medical need. Hemophilia, sickle cell disease, and spinal muscular atrophy exemplify such targets: each involves a single well-characterized genetic defect, has established natural history and clinical outcome measures, affects tissue types amenable to current delivery technologies, and imposes substantial disease burden justifying aggressive intervention. Conversely, several gene therapy programs targeting more complex diseases including Alzheimer disease, Parkinson disease, and various solid tumors have struggled to demonstrate efficacy, potentially reflecting insufficient understanding of disease mechanisms, genetic heterogeneity, or inadequate delivery to affected tissues. The lesson appears to be that initial clinical translation should focus on diseases where target validation is strong, delivery approaches are established, and mechanisms of therapeutic benefit are well-understood, with expansion to more complex applications following proof-of-concept success.

Patient selection criteria profoundly influence clinical trial outcomes and product performance, yet optimal selection strategies remain incompletely defined for many applications. In hemophilia gene therapy trials, patients with pre-existing neutralizing antibodies to AAV vectors are excluded, and some trials further require absence of significant liver disease and absence of inhibitory antibodies to coagulation factors. These selection criteria enhance likelihood of successful transduction and sustained expression but limit generalizability to broader patient populations with more diverse characteristics. The tension between maximizing success probability in early trials through restrictive eligibility and demonstrating real-world effectiveness in heterogeneous populations represents an ongoing challenge. Post-approval expansion of eligibility criteria based on accumulating safety data may enable treatment of broader populations, though conservative initial eligibility likely remains appropriate given uncertainties.

Several critical questions remain incompletely answered despite substantial clinical experience. The long-term durability of therapeutic benefit beyond current follow-up durations remains uncertain for most gene therapies, with few products having more than 5-10 years of follow-up data. While current data suggest sustained benefit for many

applications, the possibility of late transgene expression loss, development of delayed immune responses, or age-related changes affecting transduced cell populations necessitates continued monitoring. The optimal timing of gene therapy intervention—whether early in disease course before irreversible organ damage accumulates or later after establishing severity warranting aggressive intervention—remains debated for many conditions. Biomarkers predicting treatment response would enable more personalized patient selection and potentially improve outcomes by identifying individuals most likely to benefit, but such markers remain elusive for most applications. The potential for germline transmission of editing modifications or integration events, while expected to be extremely rare, requires ongoing assessment and has implications for genetic counseling and family planning discussions with treated patients.

Conclusions

Gene therapy has unequivocally transitioned from an experimental concept to a clinically validated and transformative therapeutic paradigm, fundamentally reshaping modern medicine's approach to disease management. The cumulative evidence reviewed in this work demonstrates that advances in viral vector engineering, genome editing technologies, and cell-based genetic interventions have enabled durable, and in some cases curative, outcomes across a spectrum of inherited and acquired diseases. The successful clinical implementation of adeno-associated virus–based therapies, lentiviral ex vivo gene correction, and CRISPR-Cas–mediated genome editing underscores the maturation of the field and validates decades of foundational molecular and translational research.

The renaissance of gene therapy has been driven by technological breakthroughs that addressed earlier limitations related to safety, delivery efficiency, and durability of gene expression. The refinement of AAV and lentiviral platforms has enabled targeted and sustained genetic modification with acceptable risk profiles, while genome editing technologies have expanded therapeutic possibilities beyond gene replacement toward precise correction of pathogenic mutations. The approval of CRISPR-based therapies and the rapid clinical translation of engineered cell therapies, particularly CAR-T cells, represent historic milestones demonstrating that genetic medicine can deliver durable clinical benefit even in diseases previously considered incurable.

At the same time, the expansion of gene therapy into broader and more complex disease indications has illuminated persistent scientific, clinical, and systemic challenges. Immunogenicity, manufacturing scalability, long-term safety surveillance, and economic sustainability remain critical determinants of therapeutic success and equitable access. The high upfront costs of approved gene therapies, while often justified by long-term clinical value, pose significant challenges for healthcare systems and necessitate innovative reimbursement and policy frameworks. Furthermore, uncertainties regarding long-term

durability, re-dosing feasibility, and late-emerging risks emphasize the need for continued vigilance and robust post-marketing surveillance.

Importantly, this study highlights that gene therapy is no longer a singular technology but rather a diverse ecosystem of platforms, each with distinct advantages, limitations, and optimal applications. The future of the field lies not only in further refinement of individual technologies but also in their strategic integration, combining delivery systems, editing modalities, and regulatory innovations to maximize therapeutic benefit while minimizing risk. As gene therapy continues to evolve, its successful integration into routine clinical practice will depend on multidisciplinary collaboration, continued scientific innovation, ethical stewardship, and health system adaptation.

Recommendations

Future research efforts should prioritize the development of next-generation gene delivery and genome editing technologies that enhance precision, reduce immunogenicity, and enable safe re-dosing where clinically necessary. Continued optimization of base editing and prime editing platforms is particularly recommended, as these approaches offer the potential to correct pathogenic mutations without inducing double-strand DNA breaks, thereby improving safety profiles and expanding applicability to a wider range of genetic disorders.

Investment in manufacturing innovation is essential to ensure scalability, reproducibility, and global accessibility of gene therapies. The adoption of closed, automated manufacturing systems, point-of-care production models, and standardized quality control assays should be accelerated to reduce production timelines, lower costs, and minimize manufacturing failures. Parallel efforts should focus on improving viral vector yield and purification efficiency to support broader application of in vivo gene therapies for common diseases.

From a clinical perspective, the establishment of standardized patient selection criteria, biomarkers predictive of therapeutic response, and harmonized long-term follow-up protocols is strongly recommended. These measures will enhance real-world effectiveness, improve safety monitoring, and facilitate comparative evaluation across gene therapy platforms. Multidisciplinary training programs for clinicians, pharmacists, and allied healthcare professionals should be expanded to ensure safe administration, monitoring, and long-term management of patients receiving gene-based treatments.

Regulatory agencies and policymakers should continue to refine adaptive approval frameworks that balance early patient access with rigorous safety oversight. Platform-based regulatory approaches and flexible pathways for ultra-rare and personalized therapies should be further developed, supported by international collaboration and data sharing. In parallel, ethical governance structures must be strengthened to address concerns related to

informed consent, long-term risk, equitable access, and responsible use of genome editing technologies.

References

1. Wang Y, Bruggeman KF, Franks S, et al. Is viral vector gene delivery more effective using biomaterials? Adv Healthcare Mater. 2021;10(1):2001238.
2. Schäfer-Korting M. Looking to the future: drug delivery and targeting in the prophylaxis and therapy of severe and chronic diseases. Handb Exp Pharmacol. 2024;284:389–411.
3. Zhao Z, Anselmo AC, Mitragotri S. Viral vector-based gene therapies in the clinic. Bioeng Transl Med. 2022;7(1):e10258.
4. Sulashvili, N., Imerlishvili, I., Kocharyan, S., Gabunia, L., Gorgaslidze, N., Buleishvili, M., Aphkhazava, D. (2025). BIOINFORMATICS APPROACHES FOR MULTI-OMICS ANALYSIS OF THE TUMOR MICROENVIRONMENT: INTEGRATING PROTEOMICS, EXOSOMES AND IMMUNE SIGNALING. *Georgian Scientists*, *7*(4), 333–385. https://doi.org/10.52340/gs.2025.07.04.18
5. Jiang L, Wang D, He Y, Shu Y. Advances in gene therapy hold promise for treating hereditary hearing loss. Mol Ther. 2023;31(4):934–50.
6. Ferrari G, Thrasher AJ, Aiuti A. Gene therapy using haematopoietic stem and progenitor cells. Nat Rev Genet. 2021;22(4):216–34.
7. Pan X, Veroniaina H, Su N, et al. Applications and developments of gene therapy drug delivery systems for genetic diseases. Asian J Pharm Sci. 2021;16(6):687–703.
8. Li C, Samulski RJ. Engineering adeno-associated virus vectors for gene therapy. Nat Rev Genet. 2020;21(4):255–72.
9. Trivedi PD, Byrne BJ, Corti M. Evolving horizons: adenovirus vectors' timeless influence on cancer, gene therapy and vaccines. Viruses. 2023;15(12):2378.
10. Matsunaga W, Gotoh A. Adenovirus as a vector and oncolytic virus. Curr Issues Mol Biol. 2023;45(6):4826–40.
11. Shirley JL, De Jong YP, Terhorst C, Herzog RW. Immune responses to viral gene therapy vectors. Mol Ther. 2020;28(3):709–22.
12. Sulashvili, N., Jadhav, R. D., Beglaryan, M., Gabunia, L., Gorgaslidze, N., Alavidze, N., Robakidze, K. (2025). The Scientific Discussion Of Key Issue Aspects Of Immunopathogenesis And Pharmacological Properties And Profiles In Relation To Adverse Drug Reactions Challenges, Focus On Multidimensional Drug-Induced Eosinophilia And Systemic Syndrome. Georgian Scientists, 7(3), 141–179. https://doi.org/10.52340/gs.2025.07.03.13.
13. Wang J-H, Gessler DJ, Zhan W, Gallagher TL, Gao G. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal Transduct Target Ther. 2024;9(1):78.

14. Fajardo-Serrano A, Rico AJ, Roda E, Honrubia A, Arrieta S, Ariznabarreta G, Chocarro J, Lorenzo-Ramos E, Pejenaute A, Vázquez A, Lanciego JL. Adeno-associated viral vectors as versatile tools for Parkinson's research, both for disease modeling purposes and for therapeutic uses. Int J Mol Sci. 2021;22(12):6389.
15. Asmamaw Mengstie M. Viral vectors for the in vivo delivery of CRISPR components: advances and challenges. Front Bioeng Biotechnol. 2022;10:895713.
16. Zhu S, Viejo-Borbolla A. Pathogenesis and virulence of herpes simplex virus. Virulence. 2021;12(1):2670–702.
17. Wilms L, Weßollek K, Peeters TB, Yazdi AS. Infections with Herpes simplex and Varicella zoster virus. JDDG: J Dtsch Dermatol Ges. 2022;20(10):1327–1351.
18. Farsimadan M, Motamedifar M. The effects of human immunodeficiency virus, human papillomavirus, herpes simplex virus-1 and -2, human herpesvirus-6 and -8, cytomegalovirus, and hepatitis B and C virus on female fertility and pregnancy. Br J Biomed Sci. 2021;78(1):1–11.
19. Au HK, Isalan M, Mielcarek M. Gene therapy advances: a meta-analysis of AAV usage in clinical settings. Front Med. 2022;8:809118.
20. Rakoczy K, Kisielewska M, Sędzik M, Jonderko L, Celińska J, Sauer N, Szlasa W, Saczko J, Novickij V, Kulbacka J. Electroporation in clinical applications—The potential of gene electrotransfer and electrochemotherapy. Appl Sci. 2022;12(21):10821.
21. Przystupski D, Ussowicz M. Landscape of cellular bioeffects triggered by ultrasound-induced sonoporation. Int J Mol Sci. 2022;23(19):11222.
22. Aphkhazava, D., Sulashvili, N., Egnatievi, I., Tupinashvili, T., & Nozadze, M. (2024). Dynamic Tumor Microenvironment Theory: A Multifaceted Approach To Tumor Research And Biochemistry. Scientific Journal „Spectri", 9(1). https://doi.org/10.52340/spectri.2024.09.01.06
23. Li T, Yang Y, Qi H, et al. CRISPR/Cas9 therapeutics: progress and prospects. Signal Transduct Target Ther. 2023;8(1):36.
24. Aljabali AaA, El-Tanani M, Tambuwala MM. Principles of CRISPR-Cas9 technology: advancements in genome editing and emerging trends in drug delivery. J Drug Deliv Sci Technol. 2024;92:105338.
25. Asmamaw M, Zawdie B. Mechanism and applications of CRISPR/Cas-9-Mediated genome editing. Biologics. 2021;15:353–61.
26. Taha EA, Lee J, Hotta A. Delivery of CRISPR-Cas tools for *in vivo* genome editing therapy: trends and challenges. J Control Release. 2022;342:345–61.
27. Sulashvili, N., Davitashvili, M., Gorgaslidze, N., Gabunia, L., Beglaryan, M., Alavidze, N., Sulashvili, M. (2024). The Scientific Discussion Of Some Issues Of Features And Challenges Of Using Of Car-T Cells In Immunotherapy. Georgian Scientists, 6(4), 263–290. https://doi.org/10.52340/gs.2024.06.04.24

28. Karvelis T, Gasiunas G, Miksys A, Barrangou R, Horvath P, Siksnys V. crRNA and tracrRNA guide Cas9-mediated DNA interference in Streptococcus thermophilus. RNA Biol. 2013;10(5):841–51.
29. Gleditzsch D, Pausch P, Müller-Esparza H, et al. PAM identification by CRISPR-Cas effector complexes: diversified mechanisms and structures. RNA Biol. 2019;16(4):504–17.
30. Shi Y-J, Duan M, Ding J-M, et al. DNA topology regulates PAM-Cas9 interaction and DNA unwinding to enable near-PAMless cleavage by thermophilic Cas9. Mol Cell. 2022;82(21):4160-4175.e4166.
31. Uddin F, Rudin CM, Sen T. CRISPR gene therapy: applications, limitations, and implications for the future. Front Oncol. 2020;10:1387.
32. Ghahri-Saremi N, Akbari B, Soltantoyeh T, Hadjati J, Ghassemi S, Mirzaei HR. Genetic modification of cytokine signaling to enhance efficacy of CAR T cell therapy in solid tumors. Front. Immunol 2021;12:738456.
33. AsmamawDejenie T, Tiruneh GMM, Dessie Terefe G, TadeleAdmasu F, Wale Tesega W, Chekol AE. Current updates on generations, approvals, and clinical trials of CAR T-cell therapy. Hum Vaccin Immunother. 2022;18(6):2114254.
34. Ahmad U, Khan Z, Ualiyeva D, et al. Chimeric antigen receptor T cell structure, its manufacturing, and related toxicities; A comprehensive review. Adv Cancer Biol - Metastasis. 2022;4:100035.
35. Hyun J-W, Lee K, Kim J-H, et al. Extracellular production of an anti-HER2 single-chain variable antibody fragment in Escherichia coli. Process Biochem. 2021;111:87–94.
36. Huang Y, Li L, Liu W, Tang T, Chen L. The progress of CAR-T therapy in cancer and beyond. STEMedicine. 2020;1(3):e47.
37. Ramos CA, Savoldo B, Dotti G. CD19-CAR trials. Cancer J. 2014;20(2):112–8.
38. Harrison AJ, Du X, Von Scheidt B, Kershaw MH, Slaney CY. Enhancing co-stimulation of CAR T cells to improve treatment outcomes in solid cancers. Immunother Adv. 2021;1(1):ltab016.
39. Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69.
40. Kandra P, Nandigama R, Eul B, et al. Utility and drawbacks of chimeric antigen receptor T cell (CAR-T) therapy in lung cancer. Front Immunol. 2022;13:903562.
41. Stone JB, Deangelis LM. Cancer-treatment-induced neurotoxicity–focus on newer treatments. Nat Rev Clin Oncol. 2016;13(2):92–105.
42. Castaman G, Motlagh H, Pezeshkpoor B. Hemophilia B: diagnosis and management. In: Dorgalaleh A, editor. Congenital bleeding disorders: diagnosis and management. Cham: Springer International Publishing; 2023. 145–171.
43. Ozelo MC, Mahlangu J, Pasi KJ, et al. Valoctocogene roxaparvovec gene therapy for hemophilia A. N Engl J Med. 2022;386(11):1013–25.

44. Konkle BA, Walsh CE, Escobar MA, et al. BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression. Blood. 2021;137(6):763–74.
45. Uddin F, Rudin CM, Sen T. CRISPR gene therapy: applications, limitations, and implications for the future. Frontiers in oncology. 2020 Aug 7;10:1387.
46. Chowdary P, Shapiro S, Makris M, et al. Phase 1–2 trial of AAVS3 gene therapy in patients with hemophilia B. N Engl J Med. 2022;387(3):237–47.
47. Sulashvili, N., Khusseyn, V., Hussin, D., Gabunia, L., Gorgaslidze, N., Sulashvili, M., Aphkhazava, D. (2025). The Scientific Talks Of Manifestation Of Exosomes And Small Particle-Based Therapeutics: A Comparative Review Of Biological And Synthetic Nanocarriers. Georgian Scientists, 7(4), 1–27. https://doi.org/10.52340/gs.2025.07.04.01
48. Gorovits B, Azadeh M, Buchlis G, et al. Evaluation of cellular immune response to adeno-associated virus-based gene therapy. AAPS J. 2023;25(3):47.
49. Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, et al. Current clinical applications of *in vivo* gene therapy with AAVs. Mol Ther. 2021;29(2):464–88.